Risk factors of endometrial cancer in patients with endometrial hyperplasia: implication for clinical treatments

[21] Weiderpass E(2019)Endometrial hyperplasia and the risk of coexistent cancer: WHO versus EIN criteria Histopathology 74 676-570

[22] Adami HO(2018)Treatment of low-risk endometrial cancer and complex atypical hyperplasia with the levonorgestrel-releasing intrauterine device Obstet Gynecol 131 109-549

[23] Anderson KE(2018)Risk of endometrial cancer and endometrial hyperplasia with atypia in asymptomatic postmenopausal women with endometrial thickness ≥ 11 mm: a systematic review and meta-analysis J Clin Ultrasound 46 565-819

[24] van den Brandt PA(2019)Risk factors for endometrial cancer or hyperplasia in adolescents and women 25 years old or younger J Pediatr Adolesc Gynecol 32 546-874

[25] Brinton LA(2006)Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study Cancer 106 812-829

[26] Chen C(2008)Biopsy histomorphometry predicts uterine myoinvasion by endometrial carcinoma: a Gynecologic Oncology Group study Hum Pathol 39 866-1099

[27] Cook LS(2016)High-risk factors and prognosis analysis of endometrial hyperplasia complicated with endometrial cancer J Pract Obstet Gynecol 32 826-474.e411

[28] Doherty JA(2019)Immunohistochemical predictive markers of response to conservative treatment of endometrial hyperplasia and early endometrial cancer: a systematic review Acta Obstet Gynecol Scand 98 1086-411

[29] Clarke MA(2019)National patterns of care and fertility outcomes for reproductive-aged women with endometrial cancer or atypical hyperplasia Am J Obstet Gynecol 221 474.e471-62

[30] Long BJ(2017)Premenopausal abnormal uterine bleeding and risk of endometrial cancer BJOG 124 404-434

[21] Weiderpass E(2019)Endometrial hyperplasia and the risk of coexistent cancer: WHO versus EIN criteria Histopathology 74 676-570

[22] Adami HO(2018)Treatment of low-risk endometrial cancer and complex atypical hyperplasia with the levonorgestrel-releasing intrauterine device Obstet Gynecol 131 109-549

[23] Anderson KE(2018)Risk of endometrial cancer and endometrial hyperplasia with atypia in asymptomatic postmenopausal women with endometrial thickness ≥ 11 mm: a systematic review and meta-analysis J Clin Ultrasound 46 565-819

[24] van den Brandt PA(2019)Risk factors for endometrial cancer or hyperplasia in adolescents and women 25 years old or younger J Pediatr Adolesc Gynecol 32 546-874

[25] Brinton LA(2006)Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study Cancer 106 812-829

[26] Chen C(2008)Biopsy histomorphometry predicts uterine myoinvasion by endometrial carcinoma: a Gynecologic Oncology Group study Hum Pathol 39 866-1099

[27] Cook LS(2016)High-risk factors and prognosis analysis of endometrial hyperplasia complicated with endometrial cancer J Pract Obstet Gynecol 32 826-474.e411

[28] Doherty JA(2019)Immunohistochemical predictive markers of response to conservative treatment of endometrial hyperplasia and early endometrial cancer: a systematic review Acta Obstet Gynecol Scand 98 1086-411

[29] Clarke MA(2019)National patterns of care and fertility outcomes for reproductive-aged women with endometrial cancer or atypical hyperplasia Am J Obstet Gynecol 221 474.e471-62

[30] Long BJ(2017)Premenopausal abnormal uterine bleeding and risk of endometrial cancer BJOG 124 404-434